• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Philips and Masimo announce innovation partnership to advance access to patient monitoring measurement technologies

    9/11/25 8:00:00 AM ET
    $MASI
    $PHG
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care
    Medical Electronics
    Health Care
    Get the next $MASI alert in real time by email

    September 11, 2025

    Amsterdam, the Netherlands – Royal Philips (NYSE:PHG, AEX: PHIA)), a global leader in health technology, and Masimo (NASDAQ:MASI) today announced that the two companies have renewed their multi-year strategic collaboration, marking a fresh chapter in their long-standing partnership. With a shared commitment to innovation and expanding access to high-quality, connected care, the two companies are taking a bold new approach in accelerating the development and delivery of next-generation patient monitoring solutions. This expanded agreement reflects our commitment to empower clinicians with smarter, more integrated technologies that support better outcomes across the continuum of care.

    Accelerating access to next-generation monitoring technologies 

    At the heart of the expanded partnership is a joint effort to integrate Masimo's advanced monitoring technologies – including SET® pulse oximetry, Radius PPG, and a range of sensor technology – into Philips' multi-parameter patient monitoring platforms. This integration supports clinicians with reliable data and actionable insights across bedside monitors, central stations, and wearable solutions, while giving them the flexibility to use their preferred measurement technologies within a single, unified system. By embedding these capabilities into Philips' monitoring ecosystem, the collaboration aims to reduce complexity, enhance interoperability, and deliver streamlined tools that support timely decision-making and continuity of care. 

     

    Building on this foundation, Philips and Masimo also plan to collaborate on the development and co-promotion of next-generation monitoring solutions that reflect emerging clinical needs and evolving market demands such as the need for greater patient mobility. These efforts are focused on advancing smart, connected care and expanding access to innovative technologies, including AI algorithms, that have the potential to improve patient care over time. 

     

    "Our priority is helping clinicians deliver the best possible care to their patients, and that means staying ahead of the curve," said Julia Strandberg, Executive Vice President and Business Leader Connected Care at Royal Philips. "This partnership allows us to respond quickly to evolving clinical needs and market trends, integrating proven technologies into solutions that are easy to use, reliable, and scalable."

    "We are excited to continue to partner with Philips to bring Masimo's newest innovations in wearables and artificial intelligence to Philips' platforms," said Katie Szyman, CEO of Masimo. "Expanding our strong, long-standing partnership with Philips allows us to build on our shared legacies of innovation and helps ensure that Masimo's best-in-class technologies reach even more patients. Together, Masimo and Philips will continue to empower clinicians to transform patient care."

    A shared commitment to innovation and impact 

    The renewed partnership underscores both companies' dedication to transforming patient care through meaningful innovation. By bringing together Philips' deep expertise in patient monitoring and Masimo's advanced noninvasive technologies, the collaboration is focused on delivering integrated, clinically validated solutions that scale to meet the needs of healthcare providers. It also aligns with Philips' broader strategy to work with industry-leading partners to enhance care delivery, improve operational efficiency, and support vendor-neutral interoperability across healthcare systems.

    For further information, please contact:

    Mark Groves

    External Relations, Philips

    Tel: +31 631 639 916

    E-mail: [email protected]

    About Royal Philips

    Royal Philips (NYSE:PHG, AEX: PHIA)) is a leading health technology company focused on improving people's health and well-being through meaningful innovation. Philips' patient- and people-centric innovation leverages advanced technology and deep clinical and consumer insights to deliver personal health solutions for consumers and professional health solutions for healthcare providers and their patients in the hospital and the home.

    Headquartered in the Netherlands, the company is a leader in diagnostic imaging, ultrasound, image-guided therapy, monitoring and enterprise informatics, as well as in personal health. Philips generated 2024 sales of EUR 18 billion and employs approximately 69,300 employees with sales and services in more than 100 countries. News about Philips can be found at www.philips.com/newscenter.

    Attachment

    • Philips patient monitors in use


    Primary Logo

    Get the next $MASI alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $MASI
    $PHG

    CompanyDatePrice TargetRatingAnalyst
    Koninklijke Philips N.V. NY Registry Shares
    $PHG
    12/17/2025Sector Perform
    RBC Capital Mkts
    Masimo Corporation
    $MASI
    11/17/2025Neutral
    BofA Securities
    Koninklijke Philips N.V. NY Registry Shares
    $PHG
    2/25/2025Neutral → Outperform
    Exane BNP Paribas
    Koninklijke Philips N.V. NY Registry Shares
    $PHG
    2/20/2025Neutral → Buy
    UBS
    Masimo Corporation
    $MASI
    12/27/2024$170.00 → $194.00Outperform
    Raymond James
    Masimo Corporation
    $MASI
    11/6/2024$170.00Mkt Perform → Outperform
    Raymond James
    Koninklijke Philips N.V. NY Registry Shares
    $PHG
    10/29/2024Underperform → Hold
    Jefferies
    Masimo Corporation
    $MASI
    6/3/2024$126.00 → $160.00Neutral → Overweight
    Piper Sandler
    More analyst ratings

    $MASI
    $PHG
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    RBC Capital Mkts initiated coverage on Philips

    RBC Capital Mkts initiated coverage of Philips with a rating of Sector Perform

    12/17/25 9:26:42 AM ET
    $PHG
    Medical Electronics
    Health Care

    BofA Securities initiated coverage on Masimo

    BofA Securities initiated coverage of Masimo with a rating of Neutral

    11/17/25 9:40:41 AM ET
    $MASI
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    Philips upgraded by Exane BNP Paribas

    Exane BNP Paribas upgraded Philips from Neutral to Outperform

    2/25/25 7:12:36 AM ET
    $PHG
    Medical Electronics
    Health Care

    $MASI
    $PHG
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Masimo to be Acquired by Danaher for $180.00 Per Share

    Masimo Corporation (NASDAQ:MASI) ("Masimo"), a leading global medical innovator, today announced that it has entered into a definitive agreement pursuant to which Danaher Corporation (NYSE:DHR) ("Danaher") will acquire Masimo for $180.00 per share in cash, representing a total consideration of $9.9 billion (the "Transaction"). The Transaction has been unanimously approved by both Masimo's Board of Directors and Danaher's Board of Directors. Masimo will become a standalone business unit and brand within Danaher's Diagnostics segment and will operate autonomously while strengthening Danaher's offering in acute care settings. Katie Szyman, Chief Executive Officer of Masimo, stated: "We loo

    2/17/26 8:02:00 AM ET
    $DHR
    $MASI
    Industrial Machinery/Components
    Industrials
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    Danaher To Acquire Masimo Corporation

    WASHINGTON, Feb. 17, 2026 /PRNewswire/ -- Danaher Corporation (NYSE:DHR), a global science and technology innovator, announced today that it has entered into a definitive agreement to acquire Masimo Corporation (NASDAQ:MASI) a leading specialty diagnostics provider of pulse oximetry and other patient monitoring solutions, primarily in acute care settings. Under the terms of the agreement, Danaher will acquire all of the outstanding shares of Masimo common stock for $180 per share in cash, or a total enterprise value of approximately $9.9 billion including assumed indebtedness and net of acquired cash. This represents a transaction multiple of approximately 18x estimated 2027 EBITDA, or 15x 2

    2/17/26 8:00:00 AM ET
    $DHR
    $MASI
    Industrial Machinery/Components
    Industrials
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    Philips introduces InkSpace Imaging's Snuggle™ flexible pediatric MRI coil for its 3.0T MR systems, helping to enhance imaging precision, efficiency and comfort

    February 12, 2026 Amsterdam, the Netherlands – Royal Philips (NYSE:PHG, AEX: PHIA)), a global leader in health technology, today announced the availability of the InkSpace Imaging Snuggle™ pediatric body array coil for Philips 3.0T MRI systems. Designed specifically for pediatric patients, the Snuggle coil has been optimized and validated for use with Philips 3.0T MRI systems, bringing enhanced comfort for children and efficient, high-quality imaging for clinicians. Young patients often find MRI exams challenging, and the Snuggle™ coil was created to make the experience more comfortable and less intimidating. Its light, blanket-like design and soft, flexible structure gently wrap around th

    2/12/26 9:00:00 AM ET
    $PHG
    Medical Electronics
    Health Care

    $MASI
    $PHG
    SEC Filings

    View All

    SEC Form DFAN14A filed by Masimo Corporation

    DFAN14A - MASIMO CORP (0000937556) (Subject)

    2/17/26 5:10:35 PM ET
    $MASI
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    SEC Form DEFA14A filed by Masimo Corporation

    DEFA14A - MASIMO CORP (0000937556) (Filer)

    2/17/26 4:33:46 PM ET
    $MASI
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    SEC Form DEFA14A filed by Masimo Corporation

    DEFA14A - MASIMO CORP (0000937556) (Filer)

    2/17/26 4:31:59 PM ET
    $MASI
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    $MASI
    $PHG
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    CEO Szyman Catherine M. exercised 11,141 shares at a strike of $132.96 and covered exercise/tax liability with 4,568 shares (SEC Form 4)

    4 - MASIMO CORP (0000937556) (Issuer)

    2/13/26 5:28:49 PM ET
    $MASI
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    EVP, Ops & Clinical Research Sampath Anand sold $2,555,570 worth of shares (18,680 units at $136.81) and exercised 30,000 shares at a strike of $37.84, increasing direct ownership by 38% to 40,909 units (SEC Form 4)

    4 - MASIMO CORP (0000937556) (Issuer)

    1/30/26 8:13:11 PM ET
    $MASI
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    CTIO & EVP of Engineering Ahmed Omar covered exercise/tax liability with 974 shares and exercised 2,474 shares at a strike of $152.43, increasing direct ownership by 85% to 3,268 units (SEC Form 4)

    4 - MASIMO CORP (0000937556) (Issuer)

    11/17/25 9:41:07 PM ET
    $MASI
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    $MASI
    $PHG
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Chairman of the Board Brennan Michelle bought $30,560 worth of shares (200 units at $152.80), increasing direct ownership by 3% to 7,318 units (SEC Form 4)

    4 - MASIMO CORP (0000937556) (Issuer)

    8/14/25 4:42:13 PM ET
    $MASI
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    Director Jellison William R bought $437,940 worth of shares (3,000 units at $145.98), increasing direct ownership by 168% to 4,790 units (SEC Form 4)

    4 - MASIMO CORP (0000937556) (Issuer)

    8/12/25 4:20:13 PM ET
    $MASI
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    $MASI
    $PHG
    Leadership Updates

    Live Leadership Updates

    View All

    Danaher To Acquire Masimo Corporation

    WASHINGTON, Feb. 17, 2026 /PRNewswire/ -- Danaher Corporation (NYSE:DHR), a global science and technology innovator, announced today that it has entered into a definitive agreement to acquire Masimo Corporation (NASDAQ:MASI) a leading specialty diagnostics provider of pulse oximetry and other patient monitoring solutions, primarily in acute care settings. Under the terms of the agreement, Danaher will acquire all of the outstanding shares of Masimo common stock for $180 per share in cash, or a total enterprise value of approximately $9.9 billion including assumed indebtedness and net of acquired cash. This represents a transaction multiple of approximately 18x estimated 2027 EBITDA, or 15x 2

    2/17/26 8:00:00 AM ET
    $DHR
    $MASI
    Industrial Machinery/Components
    Industrials
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    Philips proposes to re-appoint CEO Roy Jakobs

    February 10, 2026 Amsterdam, the Netherlands – Royal Philips (NYSE:PHG, AEX: PHIA)), a global leader in health technology, today announced that Roy Jakobs is proposed to be re-appointed as its President/Chief Executive Officer and member of the Board of Management. The decision to propose the re-appointment of Roy Jakobs reflects the Supervisory Board's recognition of the progress made since 2022 and its confidence in his leadership as Philips enters the next phase of driving profitable growth. The proposal will be submitted for approval at the upcoming Annual General Meeting of Shareholders (AGM), to be held on May 8, 2026. "Roy Jakobs has demonstrated clear leadership, strong execution

    2/10/26 12:55:00 AM ET
    $PHG
    Medical Electronics
    Health Care

    Clairity Appoints Founder Dr. Connie Lehman as Chief Executive Officer; Joe Kiani Named Chairman of the Board

    BOSTON, Jan. 21, 2026 (GLOBE NEWSWIRE) -- Clairity, a U.S.-based medical technology company advancing AI-powered breast cancer risk assessment, today announced that its founder, Connie Lehman, MD, PhD, has assumed the role of Chief Executive Officer as the company enters its next phase of clinical adoption and growth. The company also announced Joe Kiani as Chairman of the Board of Directors. These leadership appointments reflect a pivotal moment for Clairity following FDA De Novo authorization of its mammography-based AI risk prediction platform and increasing engagement with health systems and partners worldwide. Clairity's innovation aligns with national priorities to improve health o

    1/21/26 4:30:00 PM ET
    $MASI
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    $MASI
    $PHG
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13D/A filed by Masimo Corporation

    SC 13D/A - MASIMO CORP (0000937556) (Subject)

    9/25/24 4:01:23 PM ET
    $MASI
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    Amendment: SEC Form SC 13D/A filed by Masimo Corporation

    SC 13D/A - MASIMO CORP (0000937556) (Subject)

    8/30/24 4:56:53 PM ET
    $MASI
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    Amendment: SEC Form SC 13D/A filed by Masimo Corporation

    SC 13D/A - MASIMO CORP (0000937556) (Subject)

    7/17/24 5:29:36 PM ET
    $MASI
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    $MASI
    $PHG
    Financials

    Live finance-specific insights

    View All

    Masimo to be Acquired by Danaher for $180.00 Per Share

    Masimo Corporation (NASDAQ:MASI) ("Masimo"), a leading global medical innovator, today announced that it has entered into a definitive agreement pursuant to which Danaher Corporation (NYSE:DHR) ("Danaher") will acquire Masimo for $180.00 per share in cash, representing a total consideration of $9.9 billion (the "Transaction"). The Transaction has been unanimously approved by both Masimo's Board of Directors and Danaher's Board of Directors. Masimo will become a standalone business unit and brand within Danaher's Diagnostics segment and will operate autonomously while strengthening Danaher's offering in acute care settings. Katie Szyman, Chief Executive Officer of Masimo, stated: "We loo

    2/17/26 8:02:00 AM ET
    $DHR
    $MASI
    Industrial Machinery/Components
    Industrials
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    Masimo to Report Fourth Quarter and Full Year 2025 Financial Results after Market Close on Thursday, February 26

    Conference call and webcast to begin at 1:30 p.m. PT (4:30 p.m. ET) Masimo (NASDAQ:MASI) will release fourth quarter and full year 2025 financial results for the period ended January 3, 2026, after the market closes on Thursday, February 26, 2026. The conference call to review the results will begin at 1:30 p.m. PT (4:30 p.m. ET) and will be hosted by Katie Szyman, Chief Executive Officer, and Micah Young, Chief Financial Officer. To register for the conference call or the webcast, please use the link below. Upon registering, each participant will be provided with details for the call or webcast. Conference Call Registration Link (Please register to obtain the dial-in number): Masim

    2/12/26 9:00:00 AM ET
    $MASI
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    Emergency Care Holdings Acquires Philips Emergency Care Business, Launching Global Emergency Care Platform

    Transaction establishes a scalable platform positioned for consolidation and growth in a $26B global emergency medical products market Emergency Care Holdings (ECH), a platform backed by Bridgefield Capital, today announced the completion of its acquisition of the Philips Emergency Care business from Koninklijke Philips N.V. (NYSE:PHG). The business will operate as Heartstream and continue to market select products under a Philips brand license. The acquisition represents the launch of ECH's global platform strategy focused on building a leading portfolio of emergency medical technology companies serving the pre-hospital care market. The emergency medical products sector exceeds $26 bil

    1/14/26 10:31:00 AM ET
    $PHG
    Medical Electronics
    Health Care